Abstract: The present disclosure provides a compound comprising a modified tetracycline derivative, covalently coupled through a linker to a low-hydrophobicity bioactive molecule useful for treating neurodegenerative diseases, wherein the modified tetracycline derivative is optionally defined by the following formula:

Abstract: A floating platform for high-power wind turbines, comprising a concrete substructure, said concrete substructure forming the base of the platform, which remains semi-submerged in the operating position, and consisting of a square lower slab on which a series of beams and five hollow reinforced concrete cylinders are constructed, distributed at the corners and the center of said lower slab; a metal superstructure supported on the concrete substructure and forming the base for connection with the wind turbine tower, said tower being coupled at the center thereof; and metal covers covering each of the cylinders, on which the metal superstructure is supported and to which vertical pillars are secured, linked together by beams, which join at the central pillar by an element whereon the base of the wind turbine tower is secured.

Abstract: The present invention relates to a group of compounds derived from resveratrol having as substituents at least one silyl group which, in turn, can be substituted by different groups. The invention also relates to the therapeutic use of these compounds in inflammatory, neurological, and neurodegenerative diseases.

Abstract: The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS.

Abstract: The present invention provides a novel method to isolate and expand pure neural stem cells (NSCs) from cerebrospinal fluid (CSF) of premature babies with Intraventricular haemorrhage, which produces a population enriched in NSC-CSF cells free of contaminating fibroblasts and other cell types. The present invention also includes substantially pure populations of CSF-NSC cells, and their use to treat and prevent diseases and injuries, including Intraventricular haemorrhage and post-hemorrhage hydrocephalus/developmental deficits.

Abstract: A transport device for conveying passengers between first and second landing areas in a conveying direction may include a skirt member and a balustrade, which may include lower and upper sides, extending between the landing areas. The skirt member may be secured to the lower side. An endless moving handrail may form a loop. A first section of the handrail moves along the upper side of the balustrade in the conveying direction, and a second section of the handrail moves within the skirt member opposite the conveying direction. Two turnaround sections are disposed between the first and second sections near the first and second landing areas, respectively. At least one of the turnaround sections includes a cover member that renders part of the turnaround section of the handrail inaccessible to passengers. The cover member may comprise a positioning mechanism for adjustably positioning the cover member relative to the balustrade.

Abstract: A method is for prevention and/or biological control of wilt caused by Ralstonia solanacearum, by use of suitable bacteriophages. In addition a method uses the structural characterisation, genome sequence and activity of three specific lytic bacteriophages of R. solanacearum. Podovirus presents an elevated stability between 4° C. and 30° C. in an aqueous medium in the absence of a host. As a result of the high level of stability, lytic activity, elevated specificity towards R. solanacearum and the absence of activity against the microbiota associated with the plants to be protected, bacteriophages are used for the biological control of R. solanacearum in river courses and irrigation water, as well as in a method for preventing and/or controlling the wilt produced by the bacteria, in which at least one of the bacteriophages, or combinations thereof, are delivered to the plants and/or the soil in the irrigation water.

Abstract: The present invention relates to a group of compounds derived from resveratrol having as substituents at least one silyl group which, in turn, can be substituted by different groups. The invention also relates to the therapeutic use of these compounds in inflammatory, neurological, and neurodegenerative diseases.

Abstract: The present invention provides a novel method for protein manufacture wherein the protein is expressed in a host cell, and in a more specific manner relates to a method for manufacturing a protein that results in reduced levels of product-related impurities.

Abstract: A transport device for conveying passengers between first and second landing areas in a conveying direction may include a skirt member and a balustrade, which may include lower and upper sides, extending between the landing areas. The skirt member may be secured to the lower side. An endless moving handrail may form a loop. A first section of the handrail moves along the upper side of the balustrade in the conveying direction, and a second section of the handrail moves within the skirt member opposite the conveying direction. Two turnaround sections are disposed between the first and second sections near the first and second landing areas, respectively. At least one of the turnaround sections includes a cover member that renders part of the turnaround section of the handrail inaccessible to passengers. The cover member may comprise a positioning mechanism for adjustably positioning the cover member relative to the balustrade.

Abstract: A method is for prevention and/or biological control of wilt caused by Ralstonia solanacearum, by use of suitable bacteriophages. In addition a method uses the structural characterisation, genome sequence and activity of three specific lytic bacteriophages of R. solanacearum. Podovirus presents an elevated stability between 4° C. and 30° C. in an aqueous medium in the absence of a host. As a result of the high level of stability, lytic activity, elevated specificity towards R. solanacearum and the absence of activity against the microbiota associated with the plants to be protected, bacteriophages are used for the biological control of R. solanacearum in river courses and irrigation water, as well as in a method for preventing and/or controlling the wilt produced by the bacteria, in which at least one of the bacteriophages, or combinations thereof, are delivered to the plants and/or the soil in the irrigation water.

Abstract: The present invention provides a novel method for protein manufacture wherein the protein is expressed in a host cell, and in a more specific manner relates to a method for manufacturing a protein that results in reduced levels of product-related impurities.

Abstract: Provided herein are methods and compositions for inducing a somatic cell to acquire a less differentiated phenotype and for generating induced pluripotent stem cells (i PS cells) by inducing expression of ASF1A in the cell and/or by contacting the cell with GDF9. Also provided herein are compositions and methods for treating and/or diagnosing cancer and for identifying agents useful in the treatment and/or diagnosis of cancer.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: A composite membrane is provided for the separation of water with at least one separation layer of cross-linked polyvinyl alcohol, with the separation layer being subjected in a separate process step to a post-crosslinking operation with an acid or an acid-releasing compound and at least one dialdehyde.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS.

Abstract: A composite membrane is provided for the separation of water with at least one separation layer of cross-linked polyvinyl alcohol, with the separation layer being subjected in a separate process step to a post-crosslinking operation with an acid or an acid-releasing compound and at least one dialdehyde.

Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Abstract: In one embodiment, a feminine care product comprises a cover layer containing a cover material and indicia imprinted thereon, a liquid impervious bottom layer bonded to the cover layer, and an absorbent core intermediate the cover layer and the bottom layer. The indicia is formed from an ink comprising a surfactant and/or a botanical extract in an amount effective to increase the absorptive properties of bodily exudates into the cover layer as compared to the cover layer without the surfactant and/or botanical extract.